Clearside Biomedical Q4 2021 net income $18.7M on XIPERE milestones; CLS-AX trial advances

Clearside Biomedical, Inc.

Q4 2021 license revenue $25.7M (vs $11K in Q4 2020) from $20M in XIPERE milestones; net income $18.7M ($0.31/sh) vs net loss $7.1M.
Full year 2021 revenue $29.6M (vs $7.9M in 2020); net income $376K ($0.01/sh) vs net loss $18.2M in 2020.
Cash $30.4M at Dec 31, 2021 plus $10M collected in Q1 2022; expects to fund operations into Q2 2023.
CLS-AX OASIS Phase 1/2a: Cohort 3 results expected mid-2022; new Cohort 4 planned Q2 2022 to explore higher doses.
XIPERE launched by Bausch + Lomb in U.S. in Q1 2022 for uveitic macular edema after FDA approval Oct 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.